Stock CAMX CAMURUS AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Camurus AB

Equities

CAMX

SE0007692850

Real-time Estimate Cboe Europe
Other stock markets
 07:53:44 2024-06-20 EDT 		5-day change 1st Jan Change
569 SEK +2.15% Intraday chart for Camurus AB +0.98% +5.86%
05-23 Camurus' Rare Growth Disorder Drug Accepted for Review in EU MT
05-23 Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot for the Treatment of Acromegaly CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 95.88 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CAMURUS AB Stock Camurus AB
+5.86% 3.1B
B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+52.93% 803B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.27% 631B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.08% 351B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.40% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.58% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.77% 243B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.17% 228B
A+
NOVARTIS AG Stock Novartis AG
+10.35% 217B
B-
AMGEN INC. Stock Amgen Inc.
+6.24% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. CAMX Stock
  4. Ratings Camurus AB